Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2.

Acute lung injury (ALI) is an inflammation-mediated respiratory disease that is associated with a high mortality rate. In this study, a series of novel O-benzylcinnamic acid derivatives were designed and synthesized using cinnamic acid as the lead compound. We tested the preliminary anti-inflammatory activity of the compounds by evaluating their effect on inhibiting the activity of alkaline phosphatase (ALP) in Hek-Blue-TLR4 cells, in which compound L26 showed the best activity and 7-fold more active than CIN. ELISA, immunoprecipitation, and molecular docking indicated that L26 targeted MD-2 protein and competed with LPS to bind to MD-2, which resulted in the inhibition of inflammation. In the LPS-induced mouse model of ALI, L26 was found to decrease ALP activity and inflammatory cytokine TNF-α release to reduce lung injury by inhibiting the NF-κB signaling pathway. Acute toxicity experiments showed that high doses of L26 did not cause adverse reactions in mice, and it was safe in vivo. Also, the preliminary pharmacokinetic parameters of L26 were investigated in SD rats (T1/2 = 4.246 h). In summary, L26 exhibited optimal pharmacodynamic and pharmacokinetic characteristics, which suggested that L26 could serve as a potential agent for the development of ALI treatment. Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Citation

Xiang Li, Lina Yin, Jing Liao, Jun Yang, Binhao Cai, Yiming Yu, Sijia Su, Zhiteng Du, Xiaobo Li, Ying Zhou, Pan Chen, Won-Jea Cho, Nipon Chattipakorn, Aleksandr V Samorodov, Valentin N Pavlov, Fengzhi Zhang, Guang Liang, Qidong Tang. Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2. European journal of medicinal chemistry. 2023 Apr 05;252:115289

Mesh Tags

Substances

PMID: 36963290

search → result